fbpx
Mon - Fri 10:00-18:00
info@rhodiuminvestments.co.za
Johannesburg, Fourways

Heron Therapeutics (HRTX) in Focus: Stock Moves 9% Higher

Heron Therapeutics, Inc. HRTX was a big mover last session, as the company saw its shares rise 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $14.26 –$21.47 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen four positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Heron Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength

Heron Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Heron Therapeutics, Inc. Price

Heron Therapeutics, Inc. Price

Heron Therapeutics, Inc. price | Heron Therapeutics, Inc. Quote

Investors interested in the Medical – Drugs industry may consider Translate Bio, Inc. TBIO, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

More Stock News: This Is Bigger than the iPhone!            

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don’t buy now, you may kick yourself in 2021.  

Click here for the 6 trades >>

Click to get this free report

Translate Bio, Inc. (TBIO): Free Stock Analysis Report

Heron Therapeutics, Inc. (HRTX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Leave a Reply

Select your currency
ZAR South African rand